CI Stock Cash Flow Statements

Cigna Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Cigna Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31

cash flows from operating activities
shareholders' net income
adjustments to reconcile shareholders' net income
to net cash from operating activities
equity in income of subsidiaries
dividends received from subsidiaries
other liabilities
other	157,000,000	260,000,000	430,000,000	164,000,000	61,000,000	18,000,000	133,000,000	104,000,000	244,000,000	96,000,000	48,000,000	-63,000,000	-93,135,000,000	93,280,000,000	104,000,000	84,000,000	129,000,000	81,000,000	243,000,000	144,000,000	-237,000,000	68,000,000	106,000,000	83,000,000
net cash from operating activities	-1,886,000,000	1,920,000,000	46,000,000	265,000,000	4,840,000,000	2,826,000,000	2,492,000,000	5,028,000,000	2,099,000,000	3,283,000,000	1,244,000,000	2,030,000,000	-29,158,865,000,000	29,165,259,000,000	-296,000,000	1,093,000,000	4,294,000,000	895,000,000	3,274,000,000	1,887,000,000	-4,989,000,000	2,461,000,000	1,039,000,000	3,192,000,000
cash flows from investing activities
net change in amounts due from affiliates
net proceeds from short-term investments sold
net cash from investing activities	-797,000,000	1,197,000,000	-776,000,000	-640,000,000	-495,000,000	-1,337,000,000	-414,000,000	-2,983,000,000	-616,000,000											-269,000,000				475,000,000
cash flows from financing activities
net change in amounts due to affiliates
net change in commercial paper
repayment of long-term debt	-900,000,000	-700,000,000	0	-790,000,000	-2,210,000,000	-2,887,000,000	0	-80,000,000					0	0	-379,000,000	-4,199,000,000	-1,150,000,000	-2,099,000,000	-589,000,000	-4,209,000,000	338,000,000	-600,000,000	-1,740,000,000	-1,000,000,000
net proceeds on issuance of long-term debt			0	0	4,462,000,000	0	0	1,491,000,000					-42,599,205,000,000	42,599,205,000,000	-2,000,000	4,262,000,000	0	0	-5,000,000	3,470,000,000
issuance of common stock	72,000,000	69,000,000	62,000,000	40,000,000	181,000,000	54,000,000	29,000,000	30,000,000	72,000,000	100,000,000	124,000,000	93,000,000	-300,913,000,000	300,949,000,000	86,000,000	204,000,000	137,000,000	10,000,000	76,000,000	153,000,000	123,000,000	31,000,000	17,000,000	53,000,000
common dividends paid
repurchase of common stock	-1,112,000,000	-1,508,000,000	0	-990,000,000	-4,022,000,000	-624,000,000	-154,000,000	-962,000,000	-1,733,000,000	-3,500,000,000	-1,006,000,000	-1,368,000,000	-1,421,000,000	-2,611,000,000	-916,000,000	-2,794,000,000	-1,690,000,000	-1,028,000,000	-368,000,000	-956,000,000	-447,000,000	-674,000,000	-404,000,000	-462,000,000
tax withholding on stock compensation and other
net cash from financing activities	-1,333,000,000	-3,681,000,000	439,000,000	-2,309,000,000	-2,529,000,000	-2,572,000,000	-435,000,000	-37,000,000	-2,636,000,000												3,564,000,000
net increase in cash, cash equivalents and restricted cash		-555,000,000	-273,000,000	-2,687,000,000	1,807,000,000	-1,090,000,000	1,647,000,000	2,013,000,000	-1,141,000,000								4,041,000,000	-1,717,000,000	2,747,000,000	-237,000,000
cash, cash equivalents and restricted cash, beginning of year
cash, cash equivalents and restricted cash, end of year
noncash investing and financing activities:
net amounts due from affiliates settled through capital transactions
principal
1,000 million
750 million
1,250 million
1,500 million
debt extinguishment costs													-141,058,000,000	141,058,000,000	10,000,000	131,000,000	0	0	14,000,000	185,000,000
payments for debt extinguishment													0	0	-10,000,000	-126,000,000	0	0	-20,000,000	-192,000,000
net amounts due to/(from) affiliates settled through capital transactions
700 million
800 million
net income	1,632,000,000	1,409,000,000	825,000,000	1,629,000,000	-212,000,000	1,449,000,000	1,510,000,000	1,306,000,000	1,198,000,000	2,778,000,000	1,572,000,000	1,198,000,000	-42,818,932,000,000	42,821,700,000,000	1,476,000,000	1,171,000,000	4,142,000,000	1,398,000,000	1,760,000,000	1,189,000,000		1,354,000,000	1,410,000,000	1,372,000,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	682,000,000	674,000,000	650,000,000	738,000,000	741,000,000	766,000,000	755,000,000	749,000,000	735,000,000	726,000,000	759,000,000	717,000,000	-21,799,166,000,000	21,800,643,000,000	731,000,000	715,000,000	713,000,000	702,000,000	694,000,000	693,000,000		913,000,000	914,000,000	897,000,000
investment (gains) losses
deferred income tax benefit	-76,000,000	-216,000,000	-152,000,000	-97,000,000	-102,000,000	-96,000,000	-99,000,000	-108,000,000	-180,000,000
(gain) loss on sale of businesses	0	-41,000,000
net changes in assets and liabilities, net of non-operating effects:
accounts receivable	-4,193,000,000	-2,205,000,000	-3,287,000,000	-4,626,000,000	-2,687,000,000	-772,000,000	-665,000,000	-479,000,000	102,000,000	430,000,000	-1,786,000,000	-983,000,000	1,196,000,000	-806,000,000	-1,813,000,000	-1,420,000,000	1,314,000,000	-689,000,000	-1,065,000,000	-1,056,000,000		-6,000,000	-769,000,000	-396,000,000
inventories	-791,000,000	1,517,000,000	105,000,000	-543,000,000	1,015,000,000	97,000,000	-303,000,000	566,000,000	-759,000,000	-237,000,000	-281,000,000	222,000,000	-2,012,000,000	1,331,000,000	-123,000,000	247,000,000	-509,000,000	55,000,000	-146,000,000	96,000,000		137,000,000	84,000,000	440,000,000
reinsurance recoverable and other assets	-183,000,000	-219,000,000	201,000,000	-627,000,000	68,000,000	172,000,000	37,000,000	72,000,000	-492,000,000	189,000,000	-178,000,000	443,000,000	-108,000,000	135,000,000	-456,000,000	40,000,000	698,000,000	-496,000,000	238,000,000	-210,000,000		85,000,000	-301,000,000	124,000,000
insurance liabilities	-76,000,000	1,778,000,000	-89,000,000	-657,000,000	532,000,000	-245,000,000	194,000,000	1,533,000,000	-690,000,000	507,000,000	78,000,000	396,000,000	-862,773,000,000	863,063,000,000	234,000,000	443,000,000	101,000,000	257,000,000	142,000,000	341,000,000		293,000,000	-63,000,000	360,000,000
pharmacy and other service costs payable	860,000,000	135,000,000	1,159,000,000	3,183,000,000	4,637,000,000	703,000,000	1,008,000,000	539,000,000	392,000,000	244,000,000	1,198,000,000	-74,000,000	-13,570,123,000,000	13,570,961,000,000	708,000,000	415,000,000
accounts payable and accrued expenses and other liabilities	154,000,000	-1,174,000,000	-804,000,000	1,053,000,000	-1,068,000,000	699,000,000	-52,000,000	690,000,000	1,349,000,000	359,000,000	-168,000,000	34,000,000	1,334,000,000	232,000,000	-1,006,000,000	-637,000,000	1,378,000,000	-662,000,000	322,000,000	308,000,000		393,000,000	-461,000,000	91,000,000
proceeds from investments sold:
debt securities and equity securities	178,000,000	94,000,000	176,000,000	125,000,000	268,000,000	111,000,000	450,000,000	196,000,000	338,000,000	167,000,000	482,000,000	757,000,000	-10,520,008,000,000	10,521,186,000,000	474,000,000	378,000,000	245,000,000	400,000,000	882,000,000	756,000,000
investment maturities and repayments:
commercial mortgage loans	5,000,000	85,000,000	42,000,000	33,000,000	4,000,000	4,000,000	78,000,000	4,000,000	25,000,000	4,000,000	4,000,000	65,000,000	-12,534,000,000	12,618,000,000	24,000,000	72,000,000	5,000,000	4,000,000	5,000,000	5,000,000		5,000,000	80,000,000	89,000,000
other sales, maturities and repayments	100,000,000	331,000,000	116,000,000	179,000,000	272,000,000	140,000,000	153,000,000	160,000,000	133,000,000	161,000,000	266,000,000	479,000,000	-12,609,150,000,000	12,610,189,000,000	533,000,000	364,000,000	489,000,000	422,000,000	318,000,000	346,000,000		328,000,000	283,000,000	367,000,000
investments purchased or originated:
property and equipment purchases	-285,000,000	-327,000,000	-399,000,000	-370,000,000	-300,000,000	-403,000,000	-397,000,000	-408,000,000	-345,000,000	-338,000,000	-324,000,000	-288,000,000	-304,000,000	-350,000,000	-258,000,000	-242,000,000	-319,000,000	-252,000,000	-256,000,000	-267,000,000		-243,000,000	-303,000,000	-194,000,000
divestitures, net of cash sold	0	2,346,000,000				-14,000,000	5,000,000	22,000,000	-3,000,000
renewable energy tax credit equity investments	-235,000,000	-92,000,000
deposits and interest credited to contractholder deposit funds	38,000,000	36,000,000	36,000,000	41,000,000	43,000,000	31,000,000	51,000,000	45,000,000	43,000,000	37,000,000	41,000,000	43,000,000	-132,616,000,000	132,673,000,000	49,000,000	47,000,000	254,000,000	240,000,000	262,000,000	267,000,000		233,000,000	251,000,000	247,000,000
withdrawals and benefit payments from contractholder deposit funds	-73,000,000	-64,000,000	-45,000,000	-70,000,000	-65,000,000	-39,000,000	-52,000,000	-48,000,000	-59,000,000	-67,000,000	-45,000,000	-49,000,000	-29,000,000	-43,000,000	-61,000,000	-35,000,000	-243,000,000	-253,000,000	-228,000,000	-255,000,000		-303,000,000	-291,000,000	-251,000,000
net change in short-term debt	1,187,000,000	-891,000,000	833,000,000	-103,000,000	-364,000,000	1,301,000,000	192,000,000	-9,000,000	-8,000,000	-1,807,000,000	219,000,000	-463,000,000	-1,632,617,000,000	1,633,120,000,000	1,502,000,000	-1,030,000,000	-532,000,000	1,545,000,000	-773,000,000	-180,000,000		142,000,000	427,000,000	-1,048,000,000
common stock dividend paid	-401,000,000	-412,000,000	-390,000,000	-392,000,000	-401,000,000	-362,000,000	-362,000,000	-368,000,000	-334,000,000	-341,000,000	-352,000,000	-357,000,000	-324,000,000	-330,000,000	-342,000,000	-345,000,000
effect of foreign currency rate changes on cash, cash equivalents and restricted cash	26,000,000	9,000,000	18,000,000	-3,000,000	-9,000,000	-7,000,000	4,000,000	5,000,000	12,000,000	-18,000,000	-57,000,000	-23,000,000	-19,000,000	-19,000,000	-1,000,000	-26,000,000	48,000,000	8,000,000	22,000,000	-37,000,000
net decrease in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash january 1,	0	8,931,000,000	0	0	8,337,000,000	0	0	5,976,000,000	0	0	0	5,548,000,000	-102,445,166,000,000	102,445,166,000,000	0	10,245,000,000
cash, cash equivalents and restricted cash june 30,
cash and cash equivalents reclassified to assets of businesses held for sale			-624,000,000	1,035,000,000	-1,660,000,000						136,000,000	-591,000,000
cash, cash equivalents and restricted cash june 30, per consolidated balance sheets
supplemental disclosure of cash information:
income taxes paid, net of refunds	210,000,000	140,000,000	272,000,000	457,000,000	110,000,000	454,000,000	849,000,000	77,000,000	504,000,000	435,000,000	868,000,000	43,000,000	-19,159,168,000,000	19,159,935,000,000	1,351,000,000	122,000,000	429,000,000	1,218,000,000	109,000,000	81,000,000		417,000,000	1,161,000,000	29,000,000
interest paid	301,000,000	379,000,000	394,000,000	307,000,000	336,000,000	387,000,000	310,000,000	322,000,000	306,000,000	308,000,000	307,000,000	308,000,000	-9,499,859,000,000	9,500,473,000,000	308,000,000	331,000,000	327,000,000	369,000,000	348,000,000	395,000,000		392,000,000	488,000,000	377,000,000
investment losses		2,000,000
cash, cash equivalents and restricted cash, march 31,		8,376,000,000			10,144,000,000			7,989,000,000				5,060,000,000				6,544,000,000				5,174,000,000
cash, cash equivalents and restricted cash march 31, per consolidated balance sheets		8,376,000,000			8,484,000,000			7,989,000,000				4,469,000,000				6,544,000,000
realized investment losses			921,000,000	48,000,000	1,836,000,000	14,000,000	-26,000,000	56,000,000
loss on sale of businesses			87,000,000	0	19,000,000
acquisitions, net of cash acquired													3,000,000	0			-4,000,000					0
cash, cash equivalents and restricted cash, september 30,
cash, cash equivalents and restricted cash september 30, per consolidated balance sheets
cash, cash equivalents and restricted cash, june 30,
gain on sale of businesses									73,000,000
realized investment losses (gains)									0								-167,000,000	-32,000,000	-38,000,000	88,000,000
net proceeds on issuance of term loan																	0	0
repayment of term loan
cash, cash equivalents and restricted cash, december 31,
cash, cash equivalents and restricted cash december 31, per consolidated balance sheets
deferred policy acquisition costs										-22,000,000	-64,000,000	-41,000,000	-85,000,000	-65,000,000	-57,000,000	-60,000,000	-63,000,000	-67,000,000	-39,000,000	-138,000,000		-63,000,000	-48,000,000	-51,000,000
realized investment (gains) losses											95,000,000	319,000,000			-59,000,000	-1,000,000						-51,000,000	-23,000,000	-10,000,000
deferred income tax											-29,000,000	-138,000,000	-116,000,000	-24,000,000	-45,000,000	-35,000,000	-46,000,000	-81,000,000	-98,000,000	-161,000,000
divestiture, net of cash sold											0	-57,000,000
net cash (used in) investing activities											-408,000,000	-324,000,000		-710,000,000	-2,307,000,000	-717,000,000		-938,000,000			433,000,000	-304,000,000
net cash (used in) financing activities											-916,000,000	-2,171,000,000	-2,371,000,000	-1,728,000,000	-62,000,000	-4,051,000,000		-1,682,000,000	-312,000,000	-1,818,000,000			-1,773,000,000	-2,534,000,000
net (decrease) in cash, cash equivalents and restricted cash											-137,000,000	-488,000,000				-3,701,000,000
gain on sale of business
cash reclassified to assets of businesses held for sale
cash reclassified to assets of business held for sale																		-380,000,000	179,000,000	-597,000,000
pharmacy and service costs payable																		429,000,000	1,247,000,000	408,000,000		-503,000,000	269,000,000	444,000,000
cash, cash equivalents, and restricted cash january 1,																		0	0	5,411,000,000
cash, cash equivalents, and restricted cash september 30, per consolidated balance sheets
cash, cash equivalents, and restricted cash june 30, per consolidated balance sheets
cash, cash equivalents, and restricted cash march 31, per consolidated balance sheets																				4,577,000,000
shareholders’ net income
adjustments to reconcile shareholders’ net income
short-term investment purchased
proceeds on issuance of commercial paper
net increase in cash and cash equivalents																					-965,000,000	967,000,000	-1,366,000,000	1,121,000,000
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
* as described in note 4 to the consolidated financial statements, on december 20, 2018, old cigna became a wholly-owned subsidiary of cigna, and cigna became the registrant.
deferred income tax (benefit) expense																						-159,000,000	-79,000,000	-162,000,000
debt and equity securities																						603,000,000	565,000,000	1,471,000,000
effect of foreign currency rate changes on cash and cash equivalents																						-17,000,000	2,000,000	-12,000,000
cash and cash equivalents, january 1,																						0	0	3,855,000,000
cash and cash equivalents, september 30,
the accompanying notes to the consolidated financial statements (unaudited) are an integral part of these statements.
cash and cash equivalents, june 30,
cash and cash equivalents, march 31,																								4,976,000,000

We provide you with 20 years of cash flow statements for Cigna stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cigna stock. Explore the full financial landscape of Cigna stock with our expertly curated income statements.

The information provided in this report about Cigna stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.